TickerWise

NVNO — enVVeno Medical Corporation

$6.71+0.90%

Last close: · regular session

Last 60 sessions

NVNO closed at $6.71 (+0.90%) on Oct 26, 2026. Active shelf registration (S-3, Aug 2026). Float: 582.5K shares. Latest SEC filing: S-3 on Aug 21, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for NVNO in the TickerWise workspace.

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Company profile

Latest SEC filings for NVNO

Related companies

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.